Litcius/Paper detail

Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

Taku Kobayashi, Satoshi Motoya, Shirô Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi∥, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino

2021˜The œLancet. Gastroenterology & hepatology64 citationsDOI

Topics & Concepts

DiscontinuationInfliximabUlcerative colitisOpen labelMedicineRandomized controlled trialInternal medicineDiseaseInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesLiver Diseases and Immunity